Related Experiment Video
Updated: Dec 8, 2025
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
The development, optimization and validation of an ELISA bioanalytical method for the determination of Cetuximab in
Jamil Hantash1, Mary Smidt1, Ronald R Bowsher1
1Millipore, Inc., 15 Research Park Dr. St. Charles, MO 63304, USA. jamil_hantash@millipore.com mary_smidt@millipore.com ron_bowsher@millipore.com.
Cetuximab is a chimeric IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR). Additionally, Cetuximab, used in combination therapy, potentiates the effects of chemotherapy and radiation therapy in eradicating well-established tumors. Recently, a combination of Cetuximab and newly developed chemotherapeutic candidate drugs is being investigated for use as a new-generation chemotherapy cocktail. Therefore, there is an increasing need for a highly selective immunoassay to detect Cetuximab at low concentration levels in human serum. We report a newly developed ELISA that is validated under FDA-GLP regulations for the detection of Cetuximab. It is highly selective and achieves a lower limit of quantitation of 0.31 µg/mL. We have validated a selective and sensitive bioanalytical method.
Cetuximab is a chimeric IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR). Additionally, Cetuximab, used in combination therapy, potentiates the effects of chemotherapy and radiation therapy in eradicating well-established tumors. Recently, a combination of Cetuximab and newly developed chemotherapeutic candidate drugs is being investigated for use as a new-generation chemotherapy cocktail. Therefore, there is an increasing need for a highly selective immunoassay to detect Cetuximab at low concentration levels in human serum. We report a newly developed ELISA that is validated under FDA-GLP regulations for the detection of Cetuximab. It is highly selective and achieves a lower limit of quantitation of 0.31 µg/mL. We have validated a selective and sensitive bioanalytical method.
More Related Videos
09:32Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
07:52Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
